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Carcinoembryonic antigen assessment 
during the perioperative period in 
patients with colorectal cancer in Poland 
AbstrACt
Introduction. Carcinoembryonic antigen (CEA) concentration is often elevated during the course of colorectal 
cancer. Assessment of the CEA level in this group of patients is recommended pre- and post-surgery, during 
systemic therapy, and  further follow-up. A high preoperative level of CEA is a negative prognostic factor. The 
aim of the study was to determine the prevalence of CEA evaluation in the perioperative diagnostics in patients 
with colorectal cancer in Poland. 
Materials and methods. The analysis included 620 patients with stage III colorectal cancer, who underwent radical 
surgery in five Polish oncological centres during 2000–2014. The analysis of the clinical practice concerning the 
determination of CEA was based on the available medical records involving the pre- and post-operative period.
Results. The determination of the CEA level before the surgery was performed in only 200 patients (32%), and 
in 528 patients (85%) following resection and before starting the adjuvant systemic chemotherapy. In 74% of 
patients the preoperative CEA level exceeded 5 ng/mL (median 10.5 ng/mL; standard deviation 4.4–22.5). After 
the surgical procedure in more than 85% of patients the CEA level was within to the recommended normal value 
of 5 mg/mL (median 1.9; standard deviation 1.1–3.4).
Conclusions. Preoperative CEA level is scarcely determined in patients with colorectal cancer in Polish centres, 
which may impede further monitoring of the disease course. These results suggest the need for better adherence 
to the recommendations concerning the pre- and postoperative diagnostics in this group of patients. 
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Introduction
Colorectal cancer (CRC) is one of the most com-
monly diagnosed malignant neoplasms and one of the 
main cause of cancer deaths [1]. The morbidity rate of 
colorectal cancer is gradually increasing in the majority 
of countries worldwide. This phenomenon may result 
from aging of population, detrimental diet (high in red 
meat, animal fats, highly-processed carbohydrates), and 
obesity [2, 3]. The level of the carcinoembryonic antigen 
(CEA) is often increased in CRC. CEA is a glycopro-
tein produced in high amounts by the lining cells of the 
gastrointestinal tract and of the pancreas during foetal 
life. After the child’s birth the antigen secretion is almost 
totally discontinued and its concentration in adults’blood 
is trace [4]. CEA level assessment in patients with CRC is 
recommended pre- and postoperatively, during systemic 
therapy, and in long term follow-up [5–8]. The normal 
CEA level in non-smoking subjects is up to 5 ng/mL (in 
smokers — up to 10 ng/mL) [5–8]. A high preoperative 
CEA level is a negative prognostic factor [4–11]. There 
are no evidence based Polish data concerning the inci-
dence of the pre- and postoperative determination of 
CEA levels in patients with CRC. The aim of this study 
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Table 1. Clinical characteristics of the analysed group of 
patients (n = 620)
Clinical feature n (%)
Age at the time of diagnosis (years)
Median
Range
62.6
25–85
Sex
Females
Males 
295 (47.6)
325 (52.4)
Localisation of the primary tumour
Caecum
Ascending colon
Hepatic flexure
Transverse colon
Splenic flexure
Descending colon
Sigmoid colon
Non data
108 (17.4)
93 (15.0)
41 (6.6)
45 (7.3)
30 (4.8)
27 (4.4)
275 (44.4)
1 (0.2)
Table 2. The determination of the carcinoembryonic antigen 
(CEA) level [ng/mL] pre- and postoperatively 
Preoperative CEA concentration [ng/mL] 200 (32.3)
< 5
≥ 5
No evaluation
53 (26.5)
147 (73.5)
420 (67.7)
Postoperative CEA concentration (before 
the start of chemotherapy) [ng/mL]
528 (85.2)
< 5
≥ 5
No evaluation
450 (85.2)
78 (14.8)
92 (14.8)
was to evaluate the clinical practice in this scope of di-
agnostics in a large group of patients treated in several 
Polish oncological centres.
Materials and methods
The analysis included 620 patients with stage III CRC, 
who underwent radical surgery in five Polish oncological 
centres during 2000–2014. This review constitutes part 
of a bigger scientific programme that aims to evaluate 
other factors related to the postoperative chemotherapy 
in CRC. The clinical stage of disease was estimated 
based on the seventh version of the pTNM (tumour, 
nodes, metastases) classification, developed by the 
Union International Cancer Control (UICC) [12]. The 
CEA level was evaluated by the standard methods used 
in each specific oncology centre. Data concerning the 
pre- and postoperative CEA levels were based on the 
analysis of the available medical records. The influence 
of the pre- and postoperative CEA level on the overall 
survival and disease-free survival rates was also assessed. 
Due to the incomplete data concerning cigarette smoking 
the upper limit of the CEA level for the whole cohort 
was determined as 5 ng/mL. The statistical analysis was 
performed with use of STATA software (version 1.1), 
based on the data introduced into a specially prepared 
database. The time of observation was defined in months 
from the diagnosis of the neoplastic disease to the last 
information about the patient or death of the patient. 
The disease-free survival (DFS) time was defined as the 
period from the first adjuvant chemotherapy course to 
the progression of the disease (local reoccurrence and/or 
distant metastases). The overall survival (OS) time repre-
sented the period from the start of the adjuvant therapy to 
the death of patients, regardless of the cause of death, or 
to the last contact with the patient. In the analysis of our 
data the level of significance was determined as p = 0.05. 
results
The analysed group of 620 patients included 325 fe-
males (52%) and 295 males (48%). The range of age 
at the time of diagnosis was 25 to 85 years (median 
63 years). The most common localisation of the tumour 
was the sigmoid colon (275 patients; 44%). Caecum and 
ascending colon cancer was diagnosed in 108 (17%) 
and 93 (15%) patients, respectively. The disease was 
also localised in transverse colon in 45 patients (7.3%), 
hepatic flexure in 41 patients (6.6%), splenic flexure in 
30 patients (4.8%), and descending colon in 27 patients 
(4.4%). In one patient the precise localisation of the 
tumour was not determined.The median observation 
time from the diagnosis of the neoplastic disease was 
52.5 months (range from 36.5 months to 77.6 months). 
The clinical characteristics of this group are presented in 
Table 1. Preoperative assessment of the CEA level was 
done in only 200 patients (32%); and postoperatively, 
before adjuvant systemic therapy, the test was performed 
in 528 patients (85%) (Table 2). In 74% of patients the 
preoperative CEA level did not exceed 5 ng/mL, and 
the median value was 10.5 ng/mL (standard deviation 
4.4–22.5). The postoperative CEA level in more than 
85% of patients was within the proposed normal limit 
of 5 ng/mL (median 1.9; standard deviation 1.1–3.4). In 
univariate analysis no correlation between the pre- and 
postoperative CEA level and DFS was observed. On the 
other hand, the increased CEA level at the beginning 
of adjuvant chemotherapy correlated with a shorter OS 
in the univariate analysis [risk score = 1.02 (95% confi-
dence interval 1.01–1.03); p = 0.0030]. This correlation 
was not significant in the multivariate analysis (Fig. 1).
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Figure 1. The influence of the carcinoembryonic antigen (CEA) level before the start of adjuvant chemotherapy on the overall 
survival; univariate analysis
Discussion
CEA is a standard serum tumour marker used 
in the diagnostics of patients with CRC. The CEA 
level is strongly associated with tumour burden, which 
makes this marker useful in the disease monitoring 
[4, 6, 8–11, 13, 14]. Following Polish and international 
recommendations, the CEA level assessment should 
be performed pre- and postoperatively and during the 
further follow-up phase [5–8, 15]. Due to the insuffi-
cient sensitivity and specificity of the CEA test, it is not 
used as a screening tool for colorectal cancer. A high 
preoperative and postoperative CEA level is a negative 
predictive factor [4, 6, 8–11, 13, 16–25].
In the presented paper the CEA level in patients with 
CRC was determined prior to surgical procedure in only 
30% of patients. More frequently (85% of patients) the 
evaluation was performed after the operative procedure 
and before adjuvant systemic therapy. Patients with 
clinical stage III of CRC were included only, because 
they participated in another scientific project. We can 
assume, with high likelihood, that these results would be 
similar in patients in other clinical stages of the disease. 
A similar situation had been previously reported in some 
other reviews. As an example, we can cite the results of 
the analysis of data from the 17th Registry: The Surveil-
lance, Epidemiology, and End Results (SEER) in the 
United States of America in 2004, which showed that 
the preoperative CEA level was determined only in 50% 
of patients [13], and the frequency of the CEA evalua-
tion differed in different states (from 28% in Georgia 
to 68% in Hawaii) [13]. Our paper includes a numerous 
group of patients undergoing routine treatment in five 
Polish oncological centres, but it does not permit us to 
draw univocal conclusions for the whole population of 
patients with CRC. Nevertheless, the presented results 
suggest a need for implementation of mandatory as-
sessment of the preoperative CEA level in patients with 
CRC admitted to internal diseases departments or to 
surgical wards.The evaluation of the serum CEA level 
is a relatively inexpensive test, which is accessible in the 
majority of diagnostic laboratories.
In this review no correlation between the CEA level 
and the DFS was shown. The negative correlation of 
the increased CEA level and the OS reported by the 
univariate analyses was not confirmed in the multivariate 
regression model.The lack of these correlations could 
result from the low power of the applied statistical test 
due to the relatively low number of patients and the 
incomplete data concerning the pre- and postoperative 
CEA evaluation.
Conclusions
In the clinical practice of Polish oncological centres, 
in nearly 70% of patients with CRC the CEA level is 
not tested in the preoperative phase, which is inconsist-
ent with national and international recommendations 
[5–8, 15]. It is advisable to take actions to change 
this situation. The American Committee on Cancer 
(AJCC) postulates inclusion of the evaluation of the 
CEA level into the TNM classification of colorectal 
cancer [13, 26].
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